Your browser doesn't support javascript.
Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.
Lai, Samuel K; McSweeney, Morgan D; Pickles, Raymond J.
  • Lai SK; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA; UNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology & Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Inhalon Biopharma, Research Triangle Park, NC 27707, USA. Electronic address: l
  • McSweeney MD; Inhalon Biopharma, Research Triangle Park, NC 27707, USA.
  • Pickles RJ; Department of Microbiology & Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Marsico Lung Institute, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
J Control Release ; 329: 87-95, 2021 01 10.
Article in English | MEDLINE | ID: covidwho-959922
ABSTRACT
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Monoclonal Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Control Release Journal subject: Pharmacology Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Monoclonal Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: J Control Release Journal subject: Pharmacology Year: 2021 Document Type: Article